Meet Khanh Vu, M.D.
Khanh D. Vu, MD, FACP
Department of General Internal Medicine, Division of Internal Medicine
Present Title & Affiliation
Primary Appointment
Professor, Department of General Internal Medicine, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1999 | The University of Texas Medical School at Houston, Houston, TX, USA, MD, Internal Medicine |
| 1995 | The University of Dallas, Irving, TX, USA, BS, Biology |
Postgraduate Training
| 2011-2011 | Professional Development, Mid Career Women Faculty Professional Development Seminar, Association of American Medical Colleges, Austin, TX |
| 1999-2002 | Residency, Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX |
Board Certifications
| 2002 | Internal Medicine |
Selected Publications
Peer-Reviewed Articles
- Khanh Vu, Busaidy N, Cabanillas ME, Konopleva M, Faderl S, Thomas DA, O'Brien S, Broglio K, Ensor J, Escalante C, Andreeff M, Kantarjian H, Lavis V, Yeung SC. A randomized controlled trial of an intensive insulin regimen in patients with Accute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 12(5):355-362, 2012. e-Pub 2012. PMID: 22658895.
- Dougherty PM, Cata JP, Burton AW, Khanh Vu, Weng HR. Dysfunction in multiple primary afferent fiber subtypes revealed by quantitative sensory testing in patients with chronic vincristine-induced pain. J Pain Symptom Manage 33(2):166-79, 2007. PMID: 17280922.
Abstracts
- Khanh Vu, Yeung S-C, Thomas DA, Faderl S, Konopleva M, Busaidy N, Cabanillas M, Verma D, Escalante C, O'Brien S, Lavis V, Kantarjian H, Weiser MA. Effect of tight control of blood glucose during hyper-CVAD chemotherapy for acute lymphocytic leukemia. Blood 112(11):336, 2008.
- Verma D, Faderl S, O'Brien S, Pierce S, Cortes J, Khanh Vu, Freireich E, Keating MJ, Kantarjian HM, Ravandi F. Late relapses in acute myelogenous leukemia: Analysis of characteristics and outcome. Blood 112(11):350, 2008.
- Faderl S, Thomas DA, Ravandi F, Garcia-Manero G, Beran M, Rytting M, Koller CA, Verstovsek S, Borthakur G, Andreeff M, Kornblau S, O'Brien S, Khanh Vu, Kwari M.. Intensification of Hyper-CVAD with L-Asparaginase, Vincristine, and Dexamethasone ("augmented Hyper-CVAD") has activity in adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL). Blood 110(11):149b, 2007.
- Khanh Vu, Hubbard JC, Lin E, Faderl SH, Cortes JE, O'Brien SM, Kantarjian HM, Thomas DA.. Venothromboembolism (VTE) in patients (pts) with acute lymphocytic leukemia (ALL), Burkitt's leukemia/lymphoma (BL) or lymphoblastic lymphoma (LL). Blood 110(11):152-153b, 2007.
- Khanh Vu, Thomas DA, Hubbard JC, Faderl S, Cortes J, Cabanillas ME, Garcia-Manero G, O'Brien SM, Kantarjian HM. Incidence of venothromboembolism (VTE) in patients (pts) with acute lymphocytic leukemia (ALL), Burkitt's leukemia/lymphoma (BL) or lymphoblastic leukemia (LL). Blood 108(11), 2006.
- Faderl S, Thomas DA, Garcia-Manero G, Ravandi F, Beran M, Rytting M, Koller CA, Verstovsek S, Borthakur G, Andreeff M, Kornblau S, Khanh Vu, Jarmon R, Kantarjian HMK. Augmented hyper-CVAD in acute lymphoblastic leukemia and vincristine in adult ALL salvage: The MDACC experience with intensified L-asparaginase and vincristine in adult ALL salvage. Blood 106(11):523a, 2005.
- Cabanillas, ME, Mattiuzzi G, Thomas D, Khanh Vu, Ossa G, Garcia-Manero G, Cortes J, Giles F, O’Brien S, Kantarjian H. Invasive fungal infections (IFI) in patients (pts) receiving hyper-CVAD. J Clin Oncol 23:6727, 2004.
- Quintas-Cardama, A, Kantarjian H, O’Brien S, Khanh Vu, Garcia-Manero G, Giles F, Rios MB, Talpaz M, Cortes J. Administration of G-CSF (Filgrastim, NeupogenTM) for imatinib mesylate (GleevecTM)-induced neutropenia in chronic phase chronic myeloid leukemia (CML) patients (pts) is safe and facilitates the achievement of cytogenetic responses. Blood 102:906a, 2003.
Patient Reviews
CV information above last modified April 12, 2024